1. Evaluation and interference of serum and skin lesion levels of leukotrienes in patients with eczema.
- Author
-
Hua Z, Fei H, and Mingming X
- Subjects
- Adolescent, Adult, Benzimidazoles pharmacology, Case-Control Studies, Female, Humans, Interferon-gamma analysis, Interleukin-2 analysis, Interleukin-4 analysis, Leukotriene B4 analysis, Leukotriene B4 blood, Leukotriene C4 analysis, Leukotriene C4 blood, Leukotriene E4 analysis, Leukotriene E4 blood, Leukotrienes blood, Male, Middle Aged, Skin pathology, Treatment Outcome, Benzimidazoles administration & dosage, Eczema drug therapy, Leukotrienes analysis, Skin chemistry
- Abstract
To evaluate the levels of leukotrienes (LTs), interleukin-2 (IL-2), interleukin-4 (IL-4), interferon-gamma (IFN-gamma) in patients with eczema and observe the effects inversed by mizolastine. Serum LTB4, LTC4, IL-2, IL-4, IFN-gamma and urinary LTE4 levels were detected by enzyme-linked immunosorbent assay (ELISA) and LTB4, LTC4, LTE4 concentrations of cutis tissue were measured by reverse-phase high-pressure liquid chromatography (RP-HPLC) in 10 eczema patients and 10 healthy volunteers. Eczema patients received mizolastine 10 mg once a day for 5 days, respectively, for comparison between before and after treatment. The above markers were assayed again after treatment. Serum LTB4, LTC4, IL-2, IFN-gamma and urinary LTE4 and skin tissue LTB4, LTC4, LTE4 levels in patients are higher than those in healthy volunteers significantly (P < 0.05). But serum IL-4 level did not show significant difference between patients and normal controls (P > 0.05). Mizolastine significantly reduced serum LTB4 and IFN-gamma levels as well as skin lesion LTB4, LTC4, LTE4 concentrations. LTs are involved in the pathogenesis of eczema. Mizolastine clearly reduces LTs levels in skin lesion.
- Published
- 2006
- Full Text
- View/download PDF